Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1248-2025

ASP BIOTRACE Auto Read 60 Steam BI Process Challenge Device, REF 73135. Recall

ASP BIOTRACE Auto Read 60 Steam BI Process Challenge Device, REF 73135.

FDA recall Class II

Ongoing

FDA lists this Class II recall for ASP BIOTRACE Auto Read 60 Steam BI Process Challenge Device, REF 73135.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1248-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jan 15, 2025
FDA report date
Mar 5, 2025
Quantity in commerce
914 devices in the U.S.
Distribution
See key details
FDA cause
Labeling False and Misleading

What is being recalled?

ASP BIOTRACE Auto Read 60 Steam BI Process Challenge Device, REF 73135.

Affected model & UDI checker

Search the exact identifiers published for Z-1248-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
73135ASP BIOTRACE Auto Read 60 Steam BI Process Challenge Device, REF 73135.Check source noticeNot specified
FDA code information

Lot numbers: F40062, F40064, F40072, F40074, F40101, F40116; UDI-DI - 07798375772624 (primary packaging), 07798375772877 (secondary packaging) containing IFU Rev.A R0.

View the original FDA recall notice

Why was this product recalled?

Error in the IFU lists an incorrect incubation time on one occasion of 20 minutes rather than the correct incubation time of 60 minutes.

What actions did TERRAGENE S.A. take?

The recalling firm issued an email on 1/15/2025 to the main office of the distributor with an attached Distributor Customer Communication letter dated 1/15/2025, an Acknowledgement and Receipt Form, an updated IFU (Rev.B R01), and a User Letter for the distributor to issue to their customers. The letter to the distributor explains that all product is affected that contains version Rev.A R0 of the IFU because a discrepancy was identified in that version. The Distributor is to review their inventory records for the affected product, identify customers that received or may have received the devices and report it to the recalling firm through the provided Acknowledgement and Receipt Form via email. The Distributor is informed the product can be used according to the enclosed updated IFU (Rev.B R01). The Distributor was requested to notify their customer by using the enclosed User Letter and include the updated IFU with the User Letter. The Distributor is also informed they can continue distribution of their inventory by sending the digital user letter and the updated digital IFU with each delivery. An updated printed IFU will also be made available to users upon request. The User Letter was similar to the Distributor letter except that it instructs the user to discard older version of the IFU (Rev.A R0 and use the product according to the IFU attached to the letter and available on the firm's website. an Acknowledgement and Receipt Form was also enclosed for completion and return.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology